New York, New York–(Newsfile Corp. – September 21, 2024) – WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities […]

bookmarks

Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the U.S. Food and Drug Administration

Vaseline
September 14, 2024
0

NANJING, China, September 14, 2024 /PRNewswire/ — On September 2nd2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), […]

Related Posts

Law Firm Frank R. Cruz Announces Filing of a Securities Classification on Behalf of Investors in Stellantis NV (STLA)

ROSEN, NATIONAL LITIGATION ATTORNEYS, Encourages Iris Energy Limited Investors to Inquire About Securities Class Action Investigation – IREN

Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the U.S. Food and Drug Administration